Evidence map›Paper›PMID 29062885›Full record

ArticleClinical nutrition experimental2017

Arctigenin inhibits prostate tumor cell growth

Piwen Wang, Walter Solorzano, Tanya Diaz, Clara E Magyar, Susanne M Henning, Jaydutt V Vadgama

Open access · goldAbstract read
In one paragraph

Article in Clinical nutrition experimental, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Targeting PI3K/Akt signaling in prostate cancer therapy.Journal of cell communication and signaling · 2023
    Review
  5. Arctigenin: pharmacology, total synthesis, and progress in structure modification.Journal of enzyme inhibition and medicinal chemistry · 2022
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. MicroRNA-Mediated Health-Promoting Effects of Phytochemicals.International journal of molecular sciences · 2019
    Review
  18. Review
  19. Kangquan Recipe Regulates the Expression of BAMBI Protein via the TGF-Evidence-based complementary and alternative medicine : eCAM · 2019
    Article
  20. TIMP-3 as a therapeutic target for cancer.Therapeutic advances in medical oncology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Piwen WangDivision of Cancer Research and Training, Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA 90059.
Walter SolorzanoDivision of Cancer Research and Training, Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA 90059.
Tanya DiazDivision of Cancer Research and Training, Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA 90059.
Clara E MagyarDepartment of Pathology, School of Medicine, University of California, Los Angeles, CA, USA 90095.
Susanne M HenningCenter for Human Nutrition, School of Medicine, University of California, Los Angeles, CA, USA 90095.
Jaydutt V VadgamaDivision of Cancer Research and Training, Charles R. Drew University of Medicine and Science, Los Angeles, CA, USA 90059.
Charles R. Drew University of Medicine and Science · USUniversity of California, Los Angeles · US

Funding

Sustaining Faculty Development & Community EngagementS21MD000103 · NIMHD · CHARLES R. DREW UNIVERSITY OF MED &SCI · PI CARLISLE, DAVID M · 2001 to 2015
$73.9M
Workshop for Junior Biostatisticians in Health ResearchU54MD007598 · NIMHD · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI Jaydutt V. Vadgama · 2012 to 2026
$60.0M
UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI FREEMAN, MICHAEL R · 2002 to 2023
$42.6M
Supporting African American Churches to Promote Cancer ScreeningU54CA143931 · NCI · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI LUCAS-WRIGHT, ANNA · 2009 to 2022
$19.7M
UCLA Clinical and Translational Science InstituteKL2TR000122 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$4.5M
Increased chemoprevention by a mixture of three phytochemicals in prostate cancerR03CA208221 · NCI · CHARLES R. DREW UNIVERSITY OF MED & SCI · PI WANG, PIWEN · 2017 to 2018
$156k
NCATS NIH HHS KL2 TR000122NCATS NIH HHS UL1 TR000124NCI NIH HHS P50 CA092131NCI NIH HHS R03 CA208221NCI NIH HHS U54 CA143931NIMHD NIH HHS S21 MD000103NIMHD NIH HHS U54 MD007598
6 · The paper itself

Abstract

The low bioavailability of most phytochemicals limits their translation to humans. We investigated whether arctigenin, a novel anti-inflammatory lignan from the seeds of

Indexed as

Arctigeninchemopreventionphytochemicalprostate cancerSCID mice

Identifiers

PMID29062885
PMCPMC5650108
OpenAlexW2604728666

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.